ACET 120 120 MG
ACETAMINOPHEN : 120 MG · DIN 02230434 · PENDOPHARM DIVISION OF PHARMASCIENCE INC
Health Canada status: MARKETED
What is ACET 120?
ACET 120 120 MG contains ACETAMINOPHEN : 120 MG. It is listed in the Health Canada Drug Product Database under DIN 02230434, held by PENDOPHARM DIVISION OF PHARMASCIENCE INC, supplied as SUPPOSITORY for RECTAL administration. Health Canada currently lists it as marketed, status dated 24-Apr-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACET 120 used for?
Treatment of mild to moderate pain and the reduction of fever.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is ACET 120 called?
The same molecule, ACETAMINOPHEN (PARACETAMOL), is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| PANDA | Latin | Bahrain |
| PANDA SIX PLUS | Latin | Bahrain |
| PANDA STRONG | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02230434 |
|---|---|
| Brand name | ACET 120 |
| Generic / active ingredient | ACETAMINOPHEN : 120 MG |
| Manufacturer | PENDOPHARM DIVISION OF PHARMASCIENCE INC |
| Strength | 120 MG |
| Dosage form | SUPPOSITORY |
| Route of administration | RECTAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | N02BE01 ACETAMINOPHEN (PARACETAMOL) |
| AHFS class | 28:08.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-Apr-2013 |
| Original market date | 1998-01-05 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02230434 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2230434 |
| Brand name | ACET 120 |
| Active ingredient / INN | ACETAMINOPHEN : 120 MG |
| ATC code | N02BE01 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N02 |
| AHFS class | 28:08.92 |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| Biosimilar biologic | No |
| Market authorization holder | PENDOPHARM DIVISION OF PHARMASCIENCE INC |
How is it administered?
Adults/Children >12y: 650mg q4-6h (max 6/day). Children 1-12y: 120mg-325mg q4-6h depending on age. Rectal use only. Moisten before insertion. Consult physician if used >5 days (pain) or >3 days (fever).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15 and 25°C.
How is it supplied?
Individually sealed suppositories available in boxes of 12.
Which pack is which?
| Strength on the label | 120 MG |
|---|---|
| Dosage form | SUPPOSITORY |
| Route | RECTAL |
| Packaging as described in the monograph | Individually sealed suppositories available in boxes of 12. |
| Storage | Store between 15 and 25°C. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Contraindications
Hypersensitivity to acetaminophen or to any ingredient in the formulation or component of the container.
Warnings and precautions
Severe or fatal liver damage if recommended dose exceeded, taken with other acetaminophen products, or with 3+ alcoholic drinks daily. Rare serious skin reactions (e.g. Stevens-Johnson syndrome).
Is ACETAMINOPHEN (PARACETAMOL) in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by APOTEX INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N02BE01 ACETAMINOPHEN (PARACETAMOL). 75 of 409 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACET 160 | 160 MG | SUPPOSITORY | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02230435 |
| ACET 325 | 325 MG | SUPPOSITORY | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02230436 |
| ACET 650 | 650 MG | SUPPOSITORY | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 02230437 |
| ACETAMINOPHEN 160 MG CHEWABLE TABLETS | 160 MG | TABLET (CHEWABLE) | LABORATOIRES TRIANON INC. | MARKETED | DIN 02237562 |
| ACETAMINOPHEN 325MG TABLETS REGULAR STRENGTH | 325 MG | TABLET | CELLCHEM PHARMACEUTICALS INC. | MARKETED | DIN 02252805 |
| ACETAMINOPHEN 500 MG TABLETS EXTRA STRENGTH EASY TO SWALLOW | 500 MG | TABLET | CELLCHEM PHARMACEUTICALS INC. | MARKETED | DIN 02255251 |
| ACETAMINOPHEN 500MG TABLETS EXTRA STRENGTH | 500 MG | TABLET | CELLCHEM PHARMACEUTICALS INC. | MARKETED | DIN 02252813 |
| ACETAMINOPHEN ARTHRITIS PAIN | 650 MG | TABLET (EXTENDED-RELEASE) | PERRIGO INTERNATIONAL | MARKETED | DIN 02272482 |
| ACETAMINOPHEN CAPLETS 325 MG | 325 MG | TABLET | LABORATOIRES TRIANON INC. | MARKETED | DIN 01977415 |
| ACETAMINOPHEN CAPLETS 325 MG | 325 MG | TABLET | APOTEX INC | MARKETED | DIN 02362341 |
How much does ACETAMINOPHEN (PARACETAMOL) cost around the world?
ACETAMINOPHEN (PARACETAMOL) is listed on 2 national price registers Nexara tracks, across 64 pack listings published on 2 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 11 | 60 | 03 Sep 2026 |
| Bahrain | retail (max) | 3 | 4 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.